Bank of New York Mellon Corp Has $29.14 Million Holdings in ADMA Biologics Inc (NASDAQ:ADMA)

Bank of New York Mellon Corp lowered its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 3.5% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 1,468,609 shares of the biotechnology company's stock after selling 52,557 shares during the quarter. Bank of New York Mellon Corp owned about 0.62% of ADMA Biologics worth $29,137,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Mark Sheptoff Financial Planning LLC purchased a new position in shares of ADMA Biologics during the 4th quarter valued at approximately $35,000. Tsfg LLC purchased a new position in shares of ADMA Biologics during the 1st quarter valued at approximately $51,000. Farther Finance Advisors LLC boosted its stake in shares of ADMA Biologics by 1,149.1% during the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after buying an additional 2,505 shares during the last quarter. AlphaQuest LLC purchased a new position in shares of ADMA Biologics during the 4th quarter valued at approximately $84,000. Finally, GF Fund Management CO. LTD. purchased a new position in shares of ADMA Biologics during the 4th quarter valued at approximately $85,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Trading Down 4.9%

Shares of NASDAQ:ADMA traded down $0.86 during midday trading on Friday, reaching $16.73. The company had a trading volume of 3,840,226 shares, compared to its average volume of 3,659,237. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58. ADMA Biologics Inc has a 1-year low of $10.21 and a 1-year high of $25.67. The firm has a market cap of $3.99 billion, a price-to-earnings ratio of 19.68 and a beta of 0.43. The company has a fifty day simple moving average of $19.22 and a two-hundred day simple moving average of $18.76.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The company had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The company's revenue for the quarter was up 40.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.08 EPS. Research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Jerrold B. Grossman sold 10,000 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the sale, the director directly owned 478,194 shares of the company's stock, valued at $10,190,314.14. This trade represents a 2.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lawrence P. Guiheen sold 20,000 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the sale, the director directly owned 94,830 shares of the company's stock, valued at $1,987,636.80. This trade represents a 17.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 464,621 shares of company stock valued at $9,644,269. Corporate insiders own 3.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ADMA. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial raised their price objective on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.